The present invention discloses a process for the preparation of substituted pyridine compounds of formula (I), comprises a step in which vinylogous nitriles of formula (II), are obtained from substituted ,-unsaturated nitrile compounds of formula (III), and a further step of converting the vinylogous nitrile compounds of formula (II) into substituted pyridines of formula (I); wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and LG are as defined in the description.

##STR00001##

The present invention discloses a process for the preparation of substituted pyridine compounds of formula (I), comprises a step in which vinylogous nitriles of formula (II), are obtained from substituted ,-unsaturated nitrile compounds of formula (III), and a further step of converting the vinylogous nitrile compounds of formula (II) into substituted pyridines of formula (I); wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and LG are as defined in the description.

##STR00001##

The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.

Disclosed are compounds of formula: ##STR00001##
that inhibiting GPBP activity, making them useful as therapeutics in antibody-mediated disorders, drug-resistant cancer, inflammation, protein misfolding and ER stress-mediated disorders, and aberrant apoptosis.

Disclosed are compounds of formula: ##STR00001##
that inhibiting GPBP activity, making them useful as therapeutics in antibody-mediated disorders, drug-resistant cancer, inflammation, protein misfolding and ER stress-mediated disorders, and aberrant apoptosis.

Disclosed are an aromatic acetylene or aromatic ethylene compound, an intermediate, a preparation method, a pharmaceutical composition and a use thereof. The aromatic acetylene or aromatic ethylene compound has a significant inhibitory effect on PD-1 and PD-L1, and can effectively relieve or treat cancers and other related diseases.

##STR00001##

Disclosed are an aromatic acetylene or aromatic ethylene compound, an intermediate, a preparation method, a pharmaceutical composition and a use thereof. The aromatic acetylene or aromatic ethylene compound has a significant inhibitory effect on PD-1 and PD-L1, and can effectively relieve or treat cancers and other related diseases.

##STR00001##

The present invention relates to methods and compositions for the treatment of BAF-related disorders such as cancers and viral infections.

Provided herein are compounds and pharmaceutical compositions of formula I

##STR00001##

where R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomers of these compounds. In addition methods are provided for inhibiting the binding of an integrin to treat various pathophysiological conditions.

Provided herein are compounds and pharmaceutical compositions of formula I

##STR00001##

where R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomers of these compounds. In addition methods are provided for inhibiting the binding of an integrin to treat various pathophysiological conditions.